The Natural History of X-Linked Lymphoproliferative Disease (XLP1): Lessons from a Long-Term Survivor.
Yike JiangMihail FiranSarada L NandiwadaAnaid ReyesRebecca A MarshTiphanie P VogelJoud HajjarPublished in: Case reports in immunology (2020)
X-linked lymphoproliferative disease (XLP1) is a rare primary immunodeficiency characterized by EBV-triggered immune dysregulation, lymphoproliferation, dysgammaglobulinemia, and lymphoma. Early childhood mortality from overwhelming inflammation is expected in most patients. The only curative therapy is hematopoietic stem cell transplant (HSCT); however, whether to perform HSCT on an asymptomatic patient remains debatable. This uncertainty arises because the natural history of XLP1 patients without transplantation is not clear. In this case report, we present the natural history of XLP1 in a 43-year-old male patient who did not receive HSCT. We also review the literature on untransplanted XLP1 patients who lived into mid-adulthood. Despite surviving childhood presentations that are typically fatal, we found that these rare patients remain susceptible to manifestations of XLP1 decades later.
Keyphrases
- end stage renal disease
- case report
- ejection fraction
- newly diagnosed
- chronic kidney disease
- prognostic factors
- hematopoietic stem cell
- epstein barr virus
- systematic review
- diffuse large b cell lymphoma
- mesenchymal stem cells
- depressive symptoms
- bone marrow
- cardiovascular events
- cell therapy
- risk factors
- early life
- smoking cessation
- replacement therapy